Tribute Pharmaceuticals Canada Inc  

(Public, OTCMKTS:TBUFF)   Watch this stock  
Find more results for otc:slxcf
+0.001 (0.07%)
Apr 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.84 - 0.85
52 week 0.41 - 1.10
Open 0.84
Vol / Avg. 35,165.00/52,004.00
Mkt cap 39.23M
P/E     -
Div/yield     -
EPS -0.16
Shares 51.58M
Beta 1.75
Inst. own 12%
May 13, 2015
Q1 2015 Tribute Pharmaceuticals Canada Inc Earnings Release (Estimated) Add to calendar
Mar 3, 2015
Q4 2014 Tribute Pharmaceuticals Canada Inc Earnings Call
Mar 3, 2015
Q4 2014 Tribute Pharmaceuticals Canada Inc Earnings Release

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -74.24% -27.13%
Operating margin -50.30% -35.99%
EBITD margin - -28.84%
Return on average assets -50.70% -16.73%
Return on average equity -109.68% -26.68%
Employees 40 -
CDP Score - -


151 Steeles Ave. E.
+1-905-8761118 (Phone)
+1-416-5959593 (Fax)

Website links


Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

Officers and directors

Arnold Tenney Chairman of the Board
Age: 70
Robert Harris President, Chief Executive Officer, Director
Age: 57
Scott Langille Chief Financial Officer, Director
Age: 56
Janice M. Clarke Vice President - Finance and Administration
Age: 52
Steven H. Goldman Independent Director
Age: 57
John M. Gregory Independent Director
Age: 60
John J. Kime Independent Director
Age: 70
Francis Martin Thrasher Independent Director
Age: 61